Centhaquin - Pharmazz

Drug Profile

Centhaquin - Pharmazz

Alternative Names: PMZ-2010

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Midwestern University; Pharmazz
  • Developer Pharmazz
  • Class Antihypertensives; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haemorrhagic shock; Postoperative pain

Most Recent Events

  • 12 Nov 2016 Pharmacokinetics data from a phase I trial in Haemorrhagic shock (In volunteers) presented at the 89th Annual Scientific Sessions of the American Heart Association (ASH-2016)
  • 20 Sep 2016 Phase-I clinical trials in Postoperative pain in USA (IV) prior to September 2016 (Pharmazz pipeline, September 2016)
  • 27 Apr 2015 Pharmazz completes a phase I trial in Haemorrhagic shock (In volunteers) in India (NCT02408731)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top